The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.
Participants undergo the following process:
There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject.
These are processed into human cells for administration and injected into the subject.
Recurrent ovarian cancer
There is a cancerous lesion that can be removed by biopsy or surgery.
Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
Patient deemed unsuitable by the principal investigator
Yong Wha Moon
Lead sponsor
CHA University
Sponsor institution